/SF
SF Stock - Stifel Financial Corp.
Financial Services|Financial - Capital MarketsNYSE
$127.41+1.97%
+$2.46 (+1.97%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.87
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).68
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.74
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+8.8%upside
Target: $138.62
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$126.14 – $128.68
TARGET (TP)$138.67
STOP LOSS$117.22
RISK/REWARD1:1.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.14
52W High$133.08
52W Low$73.27
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $5.89B | $5.10B | $4.54B | $4.72B | $3.76B |
| Gross Profit | $4.88B | $4.27B | $4.30B | $4.69B | $3.66B |
| Gross Margin | 82.9% | 83.6% | 94.8% | 99.3% | 97.3% |
| Operating Income | $928.44M | $706.69M | $885.12M | $1.07B | $651.16M |
| Net Income | $731.38M | $522.54M | $662.15M | $824.86M | $503.47M |
| Net Margin | 12.4% | 10.2% | 14.6% | 17.5% | 13.4% |
| EPS | $6.67 | $4.55 | $5.74 | $7.34 | $4.49 |
Company Overview
Stifel Financial Corp., a financial services and bank holding company, provides retail and institutional wealth management, and investment banking services to individual investors, corporations, municipalities, and institutions in the United States, the United Kingdom, the rest of Europe, and Canada. It operates in three segments: Global Wealth Management, Institutional Group, and Other. The company provides private client services, including securities transaction and financial planning services; institutional equity and fixed income sales, trading and research, and municipal finance services; investment banking services, such as mergers and acquisitions, public offerings, and private placements; and retail and commercial banking services comprising personal and commercial lending programs, as well as deposit accounts. It also participates in and manages underwritings for corporate and public finance; and offers financial advisory and securities brokerage services. The company was founded in 1890 and is headquartered in St. Louis, Missouri.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
56%
Hold / Neutral
4
44%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
5 Bullish4 Neutral/Bearish
Price Targets
$106
Average Target
↓ 16.9% Downside
Now
$60
Low
$106
Average
$150
High
Based on 11 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 11th 2025 | UBS | Resumed | Buy | $150 |
| October 8th 2025 | TD Cowen | Upgrade | Buy | $131 |
| October 3rd 2025 | BMO Capital Markets | Initiation | Market Perform | $121 |
| July 31st 2025 | Citigroup | Upgrade | Buy | $135 |
| April 24th 2025 | Wolfe Research | Upgrade | Outperform | $108 |
| December 10th 2024 | JP Morgan | Initiation | Neutral | $120 |
| September 12th 2024 | Wells Fargo | Initiation | Overweight | $101 |
| July 22nd 2024 | Wolfe Research | Downgrade | Peer Perform | - |
| July 8th 2024 | TD Cowen | Downgrade | Hold | $89← $94 |
| January 4th 2024 | TD Cowen | Initiation | Outperform | $83 |
| November 22nd 2022 | UBS | Initiation | Neutral | $66 |
| October 12th 2022 | Citigroup | Initiation | Neutral | $60 |
Earnings History & Surprises
SFBeat Rate
56%
Last 18 quarters
Avg Surprise
-4.1%
EPS vs Estimate
Beats / Misses
10/8
Last 12 quarters
Latest EPS
$1.95
Q4 2025
EPS Surprise History
Q1 24
+14.5%
$1.50vs$1.31
Q2 24
+1.4%
$1.49vs$1.47
Q3 24
+3.9%
$1.60vs$1.54
Q4 24
-6.3%
$1.50vs$1.60
Q1 25
+13.2%
$2.23vs$1.97
Q2 25
-70.1%
$0.49vs$1.64
Q3 25
+6.2%
$1.71vs$1.61
Q4 25
+5.4%
$1.95vs$1.85
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 21, 2026 | — | — | — | — |
Q1 2026 | Feb 4, 2026 | $2.45 | — | — | — |
Q4 2025 | Oct 22, 2025 | $1.85 | $1.95 | +5.4% | ✓ BEAT |
Q3 2025 | Jul 30, 2025 | $1.61 | $1.71 | +6.2% | ✓ BEAT |
Q2 2025 | Apr 23, 2025 | $1.64 | $0.49 | -70.1% | ✗ MISS |
Q1 2025 | Jan 29, 2025 | $1.97 | $2.23 | +13.2% | ✓ BEAT |
Q4 2024 | Oct 23, 2024 | $1.60 | $1.50 | -6.3% | ✗ MISS |
Q3 2024 | Jul 24, 2024 | $1.54 | $1.60 | +3.9% | ✓ BEAT |
Q2 2024 | Apr 24, 2024 | $1.47 | $1.49 | +1.4% | ✓ BEAT |
Q1 2024 | Jan 24, 2024 | $1.31 | $1.50 | +14.5% | ✓ BEAT |
Q4 2023 | Oct 25, 2023 | $1.29 | $0.60 | -53.5% | ✗ MISS |
Q3 2023 | Jul 26, 2023 | $1.33 | $1.20 | -9.8% | ✗ MISS |
Q2 2023 | Apr 26, 2023 | $1.45 | $1.40 | -3.4% | ✗ MISS |
Q1 2023 | Jan 25, 2023 | $1.64 | $1.58 | -3.7% | ✗ MISS |
Q4 2022 | Oct 26, 2022 | $1.45 | $1.29 | -11.0% | ✗ MISS |
Q3 2022 | Jul 27, 2022 | $1.63 | $1.40 | -14.1% | ✗ MISS |
Q2 2022 | Apr 27, 2022 | $1.48 | $1.49 | +0.7% | ✓ BEAT |
Q1 2022 | Jan 26, 2022 | $1.89 | $2.23 | +18.0% | ✓ BEAT |
Q4 2021 | Oct 27, 2021 | $1.48 | $1.65 | +11.5% | ✓ BEAT |
Q3 2021 | Jul 28, 2021 | $1.38 | $1.70 | +23.2% | ✓ BEAT |
Latest News
Stifel Maintains Buy on Trevi Therapeutics, Raises Price Target to $18
📈 PositiveBenzinga•Dec 19, 2025, 02:54 PM•Also:
Stifel Maintains Hold on Supernus Pharmaceuticals, Raises Price Target to $55
➖ NeutralBenzinga•Dec 19, 2025, 02:53 PM•Also:
Stifel Maintains Buy on Oculis Holding, Raises Price Target to $40
📈 PositiveBenzinga•Dec 19, 2025, 02:48 PM
Stifel Maintains Hold on Nike, Lowers Price Target to $65
➖ NeutralBenzinga•Dec 19, 2025, 02:47 PM•Also:
Stifel Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52
📈 PositiveBenzinga•Dec 19, 2025, 02:45 PM•Also:
Stifel Maintains Buy on MBX Biosciences, Raises Price Target to $50
📈 PositiveBenzinga•Dec 19, 2025, 02:44 PM•Also:
Stifel Maintains Buy on FedEx, Raises Price Target to $328
📈 PositiveBenzinga•Dec 19, 2025, 02:42 PM•Also:
Stifel Maintains Hold on FactSet Research Systems, Lowers Price Target to $295
📉 NegativeBenzinga•Dec 19, 2025, 02:36 PM•Also:
Stifel Maintains Buy on Birkenstock Holding, Lowers Price Target to $58
➖ NeutralBenzinga•Dec 19, 2025, 02:33 PM•Also:
Stifel Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $48
➖ NeutralBenzinga•Dec 19, 2025, 02:28 PM•Also:
Stifel Maintains Buy on Spire Global, Lowers Price Target to $14
➖ NeutralBenzinga•Dec 18, 2025, 01:06 PM•Also:
Stifel Maintains Hold on ResMed, Lowers Price Target to $260
➖ NeutralBenzinga•Dec 18, 2025, 01:04 PM•Also:
Stifel Maintains Buy on Viavi Solutions, Raises Price Target to $20
📈 PositiveBenzinga•Dec 17, 2025, 12:29 PM•Also:
Stifel Maintains Hold on Paychex, Lowers Price Target to $126
➖ NeutralBenzinga•Dec 17, 2025, 12:28 PM•Also:
Crane shares are trading lower after Stifel maintained the stock with a Hold rating and lowered the price target from $202 to $200.
📉 NegativeBenzinga•Dec 16, 2025, 06:00 PM•Also:
Stifel Maintains Buy on XPO, Raises Price Target to $167
📈 PositiveBenzinga•Dec 16, 2025, 05:51 PM•Also:
Stifel Maintains Hold on Werner Enterprises, Raises Price Target to $26
➖ NeutralBenzinga•Dec 16, 2025, 05:49 PM•Also:
Stifel Maintains Buy on Valmont Industries, Raises Price Target to $491
📈 PositiveBenzinga•Dec 16, 2025, 05:47 PM•Also:
Mirum Pharmaceuticals shares are trading higher after Stifel maintained the stock with a Buy rating and raised the price target from $92 to $98.
📈 PositiveBenzinga•Dec 16, 2025, 05:46 PM•Also:
Stifel Maintains Hold on Universal Logistics Hldgs, Lowers Price Target to $17
📉 NegativeBenzinga•Dec 16, 2025, 05:46 PM•Also:
Frequently Asked Questions about SF
What is SF's current stock price?
Stifel Financial Corp. (SF) is currently trading at $127.41 per share. The stock has moved +1.97% today.
What is the analyst price target for SF?
The average analyst price target for SF is $138.67, based on 1 analyst.
What sector is Stifel Financial Corp. in?
Stifel Financial Corp. operates in the Financial Services sector, specifically within the Financial - Capital Markets industry. The company is traded on the NYSE exchange.
What is SF's market cap?
Stifel Financial Corp. has a market capitalization of $12.97 billion, making it a large-cap company.
Does SF pay dividends?
No, Stifel Financial Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Financial Services SectorAEG
Aegon Ltd.
$7.54
Mkt Cap: $12.0B
ALLY
Ally Financial Inc.
$45.69
Mkt Cap: $14.1B
CNA
CNA Financial Corporation
$47.43
Mkt Cap: $12.8B
EVR
Evercore Inc.
$342.36
Mkt Cap: $13.2B
FHN
First Horizon Corporation
$24.43
Mkt Cap: $12.6B
GLXY
Galaxy Digital
$24.00
Mkt Cap: $8.0B
HLI
Houlihan Lokey, Inc.
$176.56
Mkt Cap: $12.4B
JEF
Jefferies Financial Group Inc.
$61.95
Mkt Cap: $12.8B
RGA
Reinsurance Group of America, Incorporated
$205.70
Mkt Cap: $13.5B
XP
XP Inc.
$16.01
Mkt Cap: $8.4B
Explore stocks similar to SF for comparison